Supplementary Figure and Figure Legends from CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib
posted on 2023-03-31, 00:44authored byTriparna Sen, Pan Tong, C. Allison Stewart, Sandra Cristea, Aly Valliani, David S. Shames, Abena B. Redwood, You Hong Fan, Lerong Li, Bonnie S. Glisson, John D. Minna, Julien Sage, Don L. Gibbons, Helen Piwnica-Worms, John V. Heymach, Jing Wang, Lauren Averett Byers
This file contains the supplementary figures and figure legends. Figure S1: CHK1 overexpression and LY2606368 targeting efficacy in SCLC. Figure S2:Combinatorial effect of LY2606368 and cisplatin. Figure S3: Anti-tumor efficacy of LY2606368. Figure S4: Effect of LY2606368 in platinum-resistant SCLC models. Figure S5: Combinatorial effect of LY2606368 and olaparib. Figure S6 and S7: Proteomic biomarkers of LY2606368 response. Figure S8: MYC expression predicts sensitivity to LY2606368.
Funding
NIH
University of Texas MD Anderson Cancer Center Small Cell Lung Cancer Working Group and Abell Hangar Foundation Distinguished Professor Endowment
Sidney Kimmel Scholar Award
Free to Breathe
North Carolina Lung Cancer Partnership
LUNGevity Foundation
Uniting Against Lung Cancer
Jeanne F. Shelby Scholarship Fund
MD Anderson Physician Scientist Award
National Cancer Institute Cancer Clinical Investigator Team Leadership Award